These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 29321549)
1. Probing the molecular basis of hERG drug block with unnatural amino acids. Macdonald LC; Kim RY; Kurata HT; Fedida D Sci Rep; 2018 Jan; 8(1):289. PubMed ID: 29321549 [TBL] [Abstract][Full Text] [Related]
2. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping. Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760 [TBL] [Abstract][Full Text] [Related]
3. Structural implications of hERG K Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312 [TBL] [Abstract][Full Text] [Related]
4. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels. Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818 [TBL] [Abstract][Full Text] [Related]
5. Structural determinants of HERG channel block by clofilium and ibutilide. Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014 [TBL] [Abstract][Full Text] [Related]
6. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697 [TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels. Guo J; Gang H; Zhang S J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089 [TBL] [Abstract][Full Text] [Related]
8. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs. Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267 [TBL] [Abstract][Full Text] [Related]
9. Structural determinants for high-affinity block of hERG potassium channels. Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266 [TBL] [Abstract][Full Text] [Related]
10. Role of the pH in state-dependent blockade of hERG currents. Wang Y; Guo J; Perissinotti LL; Lees-Miller J; Teng G; Durdagi S; Duff HJ; Noskov SY Sci Rep; 2016 Oct; 6():32536. PubMed ID: 27731415 [TBL] [Abstract][Full Text] [Related]
11. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel. Luo F; Gu J; Chen L; Xu X Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024 [TBL] [Abstract][Full Text] [Related]
12. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration. Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039 [TBL] [Abstract][Full Text] [Related]
13. The Fast Component of hERG Gating Charge: An Interaction between D411 in the S1 and S4 Residues. Dou Y; Macdonald LC; Wu Y; Fedida D Biophys J; 2017 Nov; 113(9):1979-1991. PubMed ID: 29117522 [TBL] [Abstract][Full Text] [Related]